Dr. Strickler on the Benefit of Combining Tucatinib and Trastuzumab in HER2+ mCRC

John H. Strickler, MD, discusses the benefit of combining tucatinib and trastuzumab in HER2-positive metastatic colorectal cancer.

John H. Strickler, MD, associate professor of medicine, Duke University School of Medicine, medical oncologist, Duke Cancer Institute, discusses the benefit of combining tucatinib (Tukysa) and trastuzumab (Herceptin) in HER2-positive metastatic colorectal cancer (mCRC). 

The phase 2 MOUNTAINEER trial (NCT03043313) examined the efficacy of tucatinib alone and in combination with trastuzumab in patients with previously treated HER2-positive mCRC. The trial enrolled patients with RAS wild-type mCRC that had progressed on prior lines of therapy, Strickler says. Moreover, all patients enrolled had confirmed HER2-positive disease, Strickler adds.

Patients were initially enrolled into a pilot cohort of tucatinib and trastuzumab in combination, leading to favorable results and expansion, Strickler says. In the expansion phase, patients were randomized to tucatinib and trastuzumab, or tucatinib alone, Strickler concludes.

Related Videos
View All
Related Content